iRhythm Holdings Reports Favorable Zio Cardiac Monitoring Results
iRhythm Holdings, Inc (NASDAQ:IRTC) shared favorable results from its Zio cardiac monitoring device at the American College of Cardiology 2026 Annual Scientific Sessions. The studies showed higher rates of clinically actionable arrhythmias in patients with chronic kidney disease and diabetes, and a 2.8 times higher likelihood of atrial fibrillation detection in severely obese patients. The company also launched an education platform for healthcare professionals.
Tickers: $IRTC
Topics: cardiac monitoring market growth medical AI revenue growth Zio device